The Readout Loud

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(417)

Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it...

13 Tammi 202234min

Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict

Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict

First, emergency room physician Craig Spencer joins us to talk about how the Omicron variant is impacting New York City and what the coming months have in store. Then, we look ahead to the New Year in...

6 Tammi 202231min

Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

We've come to our last episode of the year, and first, STAT’s Helen Branswell joins us to talk about Omicron, boosters, and the past and future of the Covid-19 pandemic. Then, we'll review the year th...

16 Joulu 202135min

Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron

Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron

On this week's episode, we kick off the conversation with an update on what researchers are discovering about the Omicron variant of the coronavirus, including new findings from a study involving the ...

9 Joulu 202129min

Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Will the first Covid-19 pill be all that useful? How worrisome is Omicron? And when will it be safe to congregate? First, STAT's Matthew Herper joins us to talk about a tense debate among FDA advise...

2 Joulu 202132min

Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving

Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving

First, epidemiologist Michael Osterholm of the University of Minnesota joins us to talk about Covid-19 case counts, vaccination rates, and the state of the pandemic as we head into the holidays. Then,...

18 Marras 202135min

Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the National Institutes of Health over just who invented a Covid-19 vaccine. Then, STAT's Olivia Go...

11 Marras 202130min

Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga

Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga

STAT's Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to step down as CEO of Alnylam Pharmaceuticals after alm...

4 Marras 202128min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
mimmit-sijoittaa
rss-rahapodi
psykopodiaa-podcast
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
lakicast
hyva-paha-johtaminen
rss-rahamania
rss-paasipodi
rss-sami-miettinen-neuvottelija
rss-inderes
pomojen-suusta
rss-pinnan-alle
rss-karon-grilli
oppimisen-psykologia
rss-alanvaihtajat
rss-olen-yrittaja
rss-lentopaivakirjat